We are very excited to have the opportunity to work with Richard who has the full and enthusiastic support of the board and the management team to help lead GenomeQuest to the next level.
Westborough, MA (Vocus) September 16, 2010
GenomeQuest, Inc. today announced the appointment of Richard Resnick as Acting CEO of the company. He succeeds former CEO Ron Ranauro, who has resigned. During this transition, Resnick will retain his role as vice president of products and services at GenomeQuest.
“I want to thank Ron for his strong contributions over the past eight years. Under his leadership GenomeQuest has grown from a young start-up to a leadership position in IP sequence search and sequence data management (SDM). The company is exceptionally well positioned, both strategically and operationally, to capitalize on the industry transition to whole genome sequencing. The rest of the Board and I wish Ron the best in his future endeavors” said Sandra Panem, member of the Board of Directors and lead investor in GenomeQuest.
Panem continues, “We are very excited to have the opportunity to work with Richard who has the full and enthusiastic support of the board and the management team to help lead GenomeQuest to the next level.”
Resnick has led the company’s products and services operations since 2008. He has extensive experience building and growing innovative technology companies in the life sciences. He was previously CEO of Mosaic Bioinformatics, which was sold to NetGenics. Prior to Mosaic, Resnick was global bioinformatics software head for Wyeth, and, before that, a member of the Human Genome Project under Eric Lander at MIT. Resnick holds an M.B.A. from the Sloan School at MIT, an M.S. in Computer Science from WPI, and a B.S. in Computer Science from UMass Amherst.
“I am thrilled to accept this appointment and am eager to continue the mission of helping our customers improve health and agriculture through genomics. In particular, I feel GenomeQuest is uniquely positioned to help researchers and their organizations thrive in the new world of whole- and multi-genome analysis and, increasingly, the genomics ‘arc to clinical’” said Resnick.
“We are all enthusiastic to have Richard as our leader. He has a deep understanding of the science and the genomics market drivers - including instrumentation, computational infrastructure and software. He has demonstrated excellence in operations and under his leadership, the product and services team has delivered the world’s leading platform for SDM” said Jean-Jacques Codani, Founder and Chief Scientific Officer of GenomeQuest.
GenomeQuest, the global leader in SDM, helps genomic researchers and their organizations make great discoveries far faster. Over 160 leading life science companies use GenomeQuest for mission-critical work, including 17 of the top 20 pharmaceuticals.
The GenomeQuest SDM platform enables researchers to analyze and manage sequence data from their web browser. Bioinformatics managers can customize applications and unify their sequence data environment. IT and business managers can efficiently scale genomics across discovery operations. The core technology of the platform is the GQ-Engine -- a database engine that is purpose-built for storing, analyzing, and managing sequence data at whole- and multi-genome scale.
Learn more at http://www.genomequest.com.